Identification of novel survivin-derived CTL epitopes

Cancer Biology and Therapy

Volumn 3, Issue 2, 2004, Pages 173-179

  Reker, Sine ^a   Meier, Anders ^a   Holten Andersen, Lars ^a   Svane, Inge Marie ^b   Becker, Jürgen C ^a,c   Straten, Per Thor ^a   Andersen, Mads Hald ^a,c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cancer vaccine; CTL; Hla restriction; Immunotherapy; Survivin; Tumor antigens

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA A1 ANTIGEN; HLA A11 ANTIGEN; HLA A2 ANTIGEN; HLA A3 ANTIGEN; PEPTIDE; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; HLA A11; HLA-A11; MICROTUBULE ASSOCIATED PROTEIN; PEPTIDE FRAGMENT; TUMOR ANTIGEN; TUMOR PROTEIN;

ALLELE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; GENE LOSS; HUMAN; HUMAN CELL; RISK REDUCTION; CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; MELANOMA; METABOLISM; SKIN TUMOR;

ANTIGENS, NEOPLASM; CELLS, CULTURED; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HLA-A1 ANTIGEN; HLA-A2 ANTIGEN; HLA-A3 ANTIGEN; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 3042694145     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.2.611     Document Type: Article

References (50)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380-4.
2. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2:293-9.
3. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999; 11:263-70.
4. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46-54.
5. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96:1921-5.
6. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113:1076-81.
7. Grossman D, McNiff JM, Li F, Altieri DC. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 1999; 79:1121-6.
8. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. Analysis of human transcriptomes. Nat Genet 1999; 23:387-8.
9. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60:2805-9.
10. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58:5071-4.
11. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the anti-apoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999; 341:452-3.
12. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000; 19:617-23.
13. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000; 111:196-203.
14. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96:1921-5.
15. Andersen MH, thor Straten P. Survivin - a universal tumor antigen. Histol Histopathol 2002; 17:669-75.
16. Andersen MH, Pedersen LO, Becker JC, thor Straten P. Identification of a Cytotoxic T Lymphocyte Response to the Apoptose Inhibitor Protein Survivin in Cancer Patients. Cancer Res 2001; 61:869-72.
17. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor SP. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001; 61:5964-8.
18. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000; 60:4845-9.
19. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102:571-6.
20. Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, et al. The Apoptosis Inhibitor Protein Survivin Induces Tumor-specific CD8(+) and CD4(+) T Cells in Colorectal Cancer Patients. Cancer Res 2003; 63:4507-15.
21. Kessler JH, Mommaas B, Mutis T, Huijbers I, Vissers D, Benckhuijsen WE, et al. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum Immunol 2003; 64:245-55.
22. Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J 1986; 5:943-9.
23. McIntyre CA, Rees RC, Platts KE, Cooke CJ, Smith MO, Mulcahy KA, et al. Identification of peptide epitopes of MAGE-1, -2, -3 that demonstrate HLA-A3-specific binding. Cancer Immunol Immunother 1996; 42:246-50.
24. Gavioli R, Zhang QJ, Marastoni M, Guerrini R, Reali, E Tomatis R, et al. Effect of anchor residue modifications on the stability of HLA-A11/peptide complexes. Biochem Biophys Res Commun 1995; 206:8-14.
25. Kelly A, Powis SH, Kerr LA, Mockridge I, Elliott T, Bastin J, et al. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature 1992; 355:641-4.
26. Tan L, Andersen MH, Elliott T, Haurum JS. An improved assembly assay for peptide binding to HLA-B*2705 and H-2K(k) class I MHC molecules. J Immunol Methods 1997; 209:25-36.
27. Andersen MH, Sondergaard I, Zeuthen J, Elliott T, Haurum JS. An assay for peptide binding to HLA-Cw*0102. Tissue Antigens 1999; 54:185-90.
28. McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997; 210:149-66.
29. Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay. Cancer J Sci Am 1998; 4:316-23.
30. Berke Z, Andersen MH, Pedersen M, Fugger L, Zeuthen J, Haurum JS. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules. Leukemia 2000; 14:419-26.
31. Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, et al. Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 1994; 152:3913-24.
32. Andersen MH, Tan L, Sondergaard I, Zeuthen J, Elliott T, Haurum JS. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 2000; 55:519-31.
33. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396:580-4.
34. Altieri DC, Marchisio PC, Marchisio C. Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Lab Invest 1999;79: 1327-33.
35. Mashishi T, Gray CM. The ELISPOT assay: An easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin Chem Lab Med 2002; 40:903-10.
36. Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, et al. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer 2002; 20;98:409-14.
37. Herr W, Ranieri E, Gambotto A, Kierstead LS, Amoscato AA, Gesualdo L, et al. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci USA 1999; 96:12033-8.
38. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996; 157:2539-48.
39. Moudgil KD, Sercarz EE. Can antitumor immune responses discriminate between self and nonself? Immunol Today 1994;15:353-5.
40. Guichard G, Zerbib A, Le Gal FA, Hoebeke J, Connan F, Choppin J, et al. Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: Implications for recognition by tumor-infiltrating lymphocytes. J Med Chem 2000; 43:3803-8.
41. Pardoll DM. Cancer vaccines. Nat Med 1998; 4:525-31.
42. Clay TM, Custer MC, McKee MD, Parkhurst M, Robbins PF, Kerstann K, et al. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol 1999; 162:1749-55.
43. Rammensee HG, Bachmann J, Stevanovic S. MHC ligands and peptide motifs. Heidelberg: Springer Verlag, 1997.
44. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18:89-95.
45. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000; 20(191):961-76.
46. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
47. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002; 19(20 Suppl 4):A40-5.
48. Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 1999; 126:112-20.
49. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, et al. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71:142-7.
50. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000; 75:235-82:235-82.